Lixte Biotechnology Holdings, Inc. (LIXT)
USD 1.17
(-1.26%)
USD 1.17
(-1.26%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 4.3 Million USD | -22.51% |
| 2022 | 5.56 Million USD | 9.16% |
| 2021 | 5.09 Million USD | -2.59% |
| 2020 | 5.22 Million USD | 95.67% |
| 2019 | 2.67 Million USD | -38.39% |
| 2018 | 4.33 Million USD | 217.0% |
| 2017 | 1.36 Million USD | 215.65% |
| 2016 | 433.41 Thousand USD | -27.52% |
| 2015 | 597.97 Thousand USD | 10.88% |
| 2014 | 539.29 Thousand USD | -3.36% |
| 2013 | 558.04 Thousand USD | -68.17% |
| 2012 | 1.75 Million USD | 307.9% |
| 2011 | 429.76 Thousand USD | -77.75% |
| 2010 | 1.93 Million USD | 20.61% |
| 2009 | 1.6 Million USD | 3000.2% |
| 2008 | 51.65 Thousand USD | -91.79% |
| 2007 | 629.1 Thousand USD | -16.24% |
| 2006 | 751.06 Thousand USD | 16118.25% |
| 2005 | 4631.00 USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 3.58 Million USD | -16.7% |
| 2024 Q2 | 2.66 Million USD | -25.68% |
| 2023 Q4 | 4.3 Million USD | -17.69% |
| 2023 FY | 4.3 Million USD | -22.51% |
| 2023 Q1 | 4.33 Million USD | -22.11% |
| 2023 Q2 | 3.09 Million USD | -28.53% |
| 2023 Q3 | 5.23 Million USD | 69.13% |
| 2022 FY | 5.56 Million USD | 9.16% |
| 2022 Q2 | 8.02 Million USD | 94.86% |
| 2022 Q1 | 4.11 Million USD | -19.15% |
| 2022 Q4 | 5.56 Million USD | -18.47% |
| 2022 Q3 | 6.81 Million USD | -15.01% |
| 2021 FY | 5.09 Million USD | -2.59% |
| 2021 Q1 | 7.89 Million USD | 50.91% |
| 2021 Q3 | 6.33 Million USD | -12.55% |
| 2021 Q2 | 7.24 Million USD | -8.21% |
| 2021 Q4 | 5.09 Million USD | -19.58% |
| 2020 Q1 | 2.27 Million USD | -14.81% |
| 2020 Q2 | 1.89 Million USD | -16.89% |
| 2020 Q3 | 1.36 Million USD | -27.98% |
| 2020 Q4 | 5.22 Million USD | 283.77% |
| 2020 FY | 5.22 Million USD | 95.67% |
| 2019 Q2 | 3.61 Million USD | -8.49% |
| 2019 Q3 | 3.06 Million USD | -15.3% |
| 2019 Q4 | 2.67 Million USD | -12.84% |
| 2019 FY | 2.67 Million USD | -38.39% |
| 2019 Q1 | 3.95 Million USD | -8.81% |
| 2018 Q3 | 444.92 Thousand USD | -23.65% |
| 2018 Q1 | 854.55 Thousand USD | -37.54% |
| 2018 FY | 4.33 Million USD | 217.0% |
| 2018 Q4 | 4.33 Million USD | 874.71% |
| 2018 Q2 | 582.77 Thousand USD | -31.8% |
| 2017 Q3 | 1.65 Million USD | -20.05% |
| 2017 Q2 | 2.06 Million USD | 124.31% |
| 2017 Q1 | 920.56 Thousand USD | 112.4% |
| 2017 Q4 | 1.36 Million USD | -17.13% |
| 2017 FY | 1.36 Million USD | 215.65% |
| 2016 Q4 | 433.41 Thousand USD | -53.57% |
| 2016 FY | 433.41 Thousand USD | -27.52% |
| 2016 Q2 | 1.37 Million USD | 12.57% |
| 2016 Q1 | 1.22 Million USD | 104.81% |
| 2016 Q3 | 933.56 Thousand USD | -32.29% |
| 2015 Q4 | 597.97 Thousand USD | -41.78% |
| 2015 Q1 | 1.68 Million USD | 211.89% |
| 2015 FY | 597.97 Thousand USD | 10.88% |
| 2015 Q3 | 1.02 Million USD | -32.65% |
| 2015 Q2 | 1.52 Million USD | -9.33% |
| 2014 Q3 | 996.17 Thousand USD | -23.5% |
| 2014 Q4 | 539.29 Thousand USD | -45.86% |
| 2014 FY | 539.29 Thousand USD | -3.36% |
| 2014 Q2 | 1.3 Million USD | 593.15% |
| 2014 Q1 | 187.86 Thousand USD | -66.33% |
| 2013 Q3 | 873.82 Thousand USD | -23.66% |
| 2013 FY | 558.04 Thousand USD | -68.17% |
| 2013 Q4 | 558.04 Thousand USD | -36.14% |
| 2013 Q1 | 1.48 Million USD | -15.51% |
| 2013 Q2 | 1.14 Million USD | -22.71% |
| 2012 Q2 | 2.25 Million USD | 1018.53% |
| 2012 FY | 1.75 Million USD | 307.9% |
| 2012 Q1 | 201.57 Thousand USD | -53.1% |
| 2012 Q3 | 1.96 Million USD | -13.0% |
| 2012 Q4 | 1.75 Million USD | -10.63% |
| 2011 Q3 | 1 Million USD | -29.59% |
| 2011 Q1 | 1.68 Million USD | -12.56% |
| 2011 Q2 | 1.42 Million USD | -15.85% |
| 2011 FY | 429.76 Thousand USD | -77.75% |
| 2011 Q4 | 429.76 Thousand USD | -57.05% |
| 2010 Q4 | 1.93 Million USD | -1.46% |
| 2010 Q1 | 2.45 Million USD | 53.49% |
| 2010 Q2 | 2.16 Million USD | -12.0% |
| 2010 Q3 | 1.95 Million USD | -9.39% |
| 2010 FY | 1.93 Million USD | 20.61% |
| 2009 Q3 | 148.91 Thousand USD | -21.5% |
| 2009 Q2 | 189.69 Thousand USD | 64.77% |
| 2009 Q1 | 115.12 Thousand USD | 122.88% |
| 2009 FY | 1.6 Million USD | 3000.2% |
| 2009 Q4 | 1.6 Million USD | 975.38% |
| 2008 Q1 | 384.43 Thousand USD | -38.89% |
| 2008 FY | 51.65 Thousand USD | -91.79% |
| 2008 Q3 | 99.5 Thousand USD | -56.05% |
| 2008 Q2 | 226.41 Thousand USD | -41.1% |
| 2008 Q4 | 51.65 Thousand USD | -48.09% |
| 2007 Q2 | 376.62 Thousand USD | -52.23% |
| 2007 Q3 | 272.75 Thousand USD | -27.58% |
| 2007 Q1 | 788.36 Thousand USD | 4.97% |
| 2007 Q4 | 629.1 Thousand USD | 130.65% |
| 2007 FY | 629.1 Thousand USD | -16.24% |
| 2006 FY | 751.06 Thousand USD | 16118.25% |
| 2006 Q1 | 3035.00 USD | 0.0% |
| 2006 Q2 | 934.62 Thousand USD | 30694.86% |
| 2006 Q3 | 852.2 Thousand USD | -8.82% |
| 2006 Q4 | 751.06 Thousand USD | -11.87% |
| 2005 FY | 4631.00 USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AbCellera Biologics Inc. | 1.48 Billion USD | 99.71% |
| Alkermes plc | 2.13 Billion USD | 99.798% |
| Agenus Inc. | 313.91 Million USD | 98.627% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 99.887% |
| Aptorum Group Limited | 20.64 Million USD | 79.125% |
| Ardelyx, Inc. | 297.57 Million USD | 98.552% |
| Arrowhead Pharmaceuticals, Inc. | 765.55 Million USD | 99.437% |
| Bicycle Therapeutics plc | 595.34 Million USD | 99.276% |
| BioXcel Therapeutics, Inc. | 73.7 Million USD | 94.154% |
| ChromaDex Corporation | 54.96 Million USD | 92.161% |
| Chimerix, Inc. | 212.77 Million USD | 97.975% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | 84.76% |
| Caribou Biosciences, Inc. | 440.96 Million USD | 99.023% |
| CRISPR Therapeutics AG | 2.22 Billion USD | 99.807% |
| Precision BioSciences, Inc. | 159.78 Million USD | 97.303% |
| Dyadic International, Inc. | 8.21 Million USD | 47.579% |
| Eton Pharmaceuticals, Inc. | 31.74 Million USD | 86.425% |
| Fortress Biotech, Inc. | 167.52 Million USD | 97.428% |
| Lantern Pharma Inc. | 43.64 Million USD | 90.129% |
| HOOKIPA Pharma Inc. | 161.33 Million USD | 97.329% |
| Inhibikase Therapeutics, Inc. | 14.5 Million USD | 70.299% |
| Incyte Corporation | 6.78 Billion USD | 99.936% |
| IO Biotech, Inc. | 150.71 Million USD | 97.141% |
| Jaguar Health, Inc. | 50.76 Million USD | 91.512% |
| Novavax, Inc. | 1.85 Billion USD | 99.768% |
| Janux Therapeutics, Inc. | 380.4 Million USD | 98.867% |
| Opthea Limited | 188.79 Million USD | 97.718% |
| Ligand Pharmaceuticals Incorporated | 833.06 Million USD | 99.483% |
| ContextLogic Inc. | 423 Million USD | 98.981% |
| MiMedx Group, Inc. | 239.04 Million USD | 98.198% |
| Pyxis Oncology, Inc. | 173.72 Million USD | 97.52% |
| TransCode Therapeutics, Inc. | 5.16 Million USD | 16.656% |
| NextCure, Inc. | 129.41 Million USD | 96.671% |
| Ocuphire Pharma, Inc. | 53.94 Million USD | 92.013% |
| Oncternal Therapeutics, Inc. | 36.72 Million USD | 88.269% |
| Outlook Therapeutics, Inc. | 32.3 Million USD | 86.661% |
| Vaxcyte, Inc. | 1.4 Billion USD | 99.694% |
| PDS Biotechnology Corporation | 59.39 Million USD | 92.745% |
| Madrigal Pharmaceuticals, Inc. | 640.54 Million USD | 99.327% |
| Pharming Group N.V. | 462.85 Million USD | 99.069% |
| Pieris Pharmaceuticals, Inc. | 38.68 Million USD | 88.861% |
| Avidity Biosciences, Inc. | 628.55 Million USD | 99.315% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | 77.232% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | 77.232% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | 97.394% |
| Sol-Gel Technologies Ltd. | 45.28 Million USD | 90.486% |
| Acelyrin, Inc. | 742.69 Million USD | 99.42% |
| Salarius Pharmaceuticals, Inc. | 6.58 Million USD | 34.584% |
| SELLAS Life Sciences Group, Inc. | 6.4 Million USD | 32.709% |
| Summit Therapeutics Inc. | 202.94 Million USD | 97.877% |
| Sensei Biotherapeutics, Inc. | 74.37 Million USD | 94.207% |
| Senti Biosciences, Inc. | 119.48 Million USD | 96.394% |
| Stoke Therapeutics, Inc. | 228.34 Million USD | 98.113% |
| Syros Pharmaceuticals, Inc. | 168.17 Million USD | 97.438% |
| Alaunos Therapeutics, Inc. | 8.26 Million USD | 47.856% |
| Telomir Pharmaceuticals, Inc. Common Stock | 4.77 Million USD | 9.744% |
| Entrada Therapeutics, Inc. | 469.19 Million USD | 99.082% |
| VistaGen Therapeutics, Inc. | 123.65 Million USD | 96.516% |
| Wave Life Sciences Ltd. | 274.94 Million USD | 98.433% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | 99.089% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | 57.362% |
| Barinthus Biotherapeutics plc | 214.5 Million USD | 97.991% |
| Psyence Biomedical Ltd. | 1.13 Million USD | -280.567% |
| Phathom Pharmaceuticals, Inc. | 413.84 Million USD | 98.959% |
| Immix Biopharma, Inc. | 19.92 Million USD | 78.376% |
| Keros Therapeutics, Inc. | 370.02 Million USD | 98.836% |
| MEI Pharma, Inc. | 41.37 Million USD | 89.586% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 86.704% |
| Xeris Biopharma Holdings, Inc. | 340.79 Million USD | 98.736% |
| Rigel Pharmaceuticals, Inc. | 117.22 Million USD | 96.324% |
| Fortress Biotech, Inc. | 167.52 Million USD | 97.428% |
| Precigen, Inc. | 151.04 Million USD | 97.147% |
| Clearside Biomedical, Inc. | 34.01 Million USD | 87.334% |
| AlloVir, Inc. | 190.79 Million USD | 97.742% |
| C4 Therapeutics, Inc. | 376.45 Million USD | 98.855% |
| Fate Therapeutics, Inc. | 506.21 Million USD | 99.149% |
| ImmuCell Corporation | 43.8 Million USD | 90.165% |
| IDEAYA Biosciences, Inc. | 649.31 Million USD | 99.336% |
| Onconetix, Inc. | 88.82 Million USD | 95.149% |
| PureTech Health plc | 693.97 Million USD | 99.379% |
| VYNE Therapeutics Inc. | 97.68 Million USD | 95.589% |
| Elevation Oncology, Inc. | 89.09 Million USD | 95.164% |
| Kintara Therapeutics, Inc. | 6.2 Million USD | 30.529% |
| Seer, Inc. | 436.26 Million USD | 99.012% |
| Verrica Pharmaceuticals Inc. | 81.59 Million USD | 94.72% |
| Innoviva, Inc. | 1.24 Billion USD | 99.654% |
| Aadi Bioscience, Inc. | 132.42 Million USD | 96.746% |
| ESSA Pharma Inc. | 149.12 Million USD | 97.111% |
| GlycoMimetics, Inc. | 45.31 Million USD | 90.492% |
| GT Biopharma, Inc. | 14.1 Million USD | 69.462% |
| Inhibrx Biosciences, Inc. | 307.89 Million USD | 98.601% |
| Akebia Therapeutics, Inc. | 241.7 Million USD | 98.217% |
| Catalyst Pharmaceuticals, Inc. | 471.9 Million USD | 99.087% |
| Longboard Pharmaceuticals, Inc. | 50.69 Million USD | 91.501% |
| Orchestra BioMed Holdings, Inc. | 95.21 Million USD | 95.475% |
| Alzamend Neuro, Inc. | 631.58 Thousand USD | -582.188% |
| Rocket Pharmaceuticals, Inc. | 566.34 Million USD | 99.239% |
| Aptose Biosciences Inc. | 12.92 Million USD | 66.658% |
| ZyVersa Therapeutics, Inc. | 22.11 Million USD | 80.517% |
| Soligenix, Inc. | 9.79 Million USD | 56.022% |
| Century Therapeutics, Inc. | 360.69 Million USD | 98.805% |
| Kura Oncology, Inc. | 448.93 Million USD | 99.04% |
| TScan Therapeutics, Inc. | 272.14 Million USD | 98.417% |
| Intensity Therapeutics, Inc. | 17.29 Million USD | 75.087% |
| Ocean Biomedical, Inc. | 110.91 Million USD | 96.115% |
| CytomX Therapeutics, Inc. | 205.15 Million USD | 97.9% |
| Autolus Therapeutics plc | 375.38 Million USD | 98.852% |
| Mineralys Therapeutics, Inc. | 251.63 Million USD | 98.288% |
| EyePoint Pharmaceuticals, Inc. | 355.18 Million USD | 98.787% |
| Eterna Therapeutics Inc. | 49.13 Million USD | 91.231% |
| Adaptive Biotechnologies Corporation | 661.13 Million USD | 99.348% |
| GRI Bio, Inc. | 2.95 Million USD | -45.758% |
| Xenetic Biosciences, Inc. | 10.6 Million USD | 59.373% |
| Tenaya Therapeutics, Inc. | 170.51 Million USD | 97.473% |
| IGM Biosciences, Inc. | 423.41 Million USD | 98.982% |
| INmune Bio, Inc. | 57 Million USD | 92.441% |
| Heron Therapeutics, Inc. | 222.5 Million USD | 98.064% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | 94.867% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | 83.503% |
| Entero Therapeutics, Inc. | 6.88 Million USD | 37.404% |
| Milestone Pharmaceuticals Inc. | 75.22 Million USD | 94.272% |
| X4 Pharmaceuticals, Inc. | 147.25 Million USD | 97.074% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | 97.397% |
| Coherus BioSciences, Inc. | 629.6 Million USD | 99.316% |
| Verastem, Inc. | 149.71 Million USD | 97.122% |
| Abeona Therapeutics Inc. | 64 Million USD | 93.268% |
| Pliant Therapeutics, Inc. | 512.15 Million USD | 99.159% |
| Tonix Pharmaceuticals Holding Corp. | 154.45 Million USD | 97.21% |
| Histogen Inc. | 19.07 Million USD | 77.41% |
| Aprea Therapeutics, Inc. | 22.65 Million USD | 80.978% |
| Surrozen, Inc. | 46.08 Million USD | 90.65% |
| Organovo Holdings, Inc. | 6.34 Million USD | 32.137% |
| Ovid Therapeutics Inc. | 144.02 Million USD | 97.008% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | 63.492% |
| CASI Pharmaceuticals, Inc. | 75.26 Million USD | 94.276% |
| Cadrenal Therapeutics, Inc. Common Stock | 8.51 Million USD | 49.425% |
| Centessa Pharmaceuticals plc | 362.96 Million USD | 98.813% |
| Hepion Pharmaceuticals, Inc. | 18.09 Million USD | 76.188% |
| Arcturus Therapeutics Holdings Inc. | 429.4 Million USD | 98.997% |
| BioRestorative Therapies, Inc. | 12.61 Million USD | 65.836% |
| Apollomics, Inc. | 55.38 Million USD | 92.221% |
| Amarin Corporation plc | 831.68 Million USD | 99.482% |
| Mesoblast Limited | 669.15 Million USD | 99.356% |
| Turnstone Biologics Corp. | 112.81 Million USD | 96.181% |
| Kymera Therapeutics, Inc. | 575.75 Million USD | 99.252% |
| Synaptogenix, Inc. | 31.11 Million USD | 86.152% |
| Tiziana Life Sciences Ltd | 12.18 Million USD | 64.637% |
| Aurinia Pharmaceuticals Inc. | 548.06 Million USD | 99.214% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | 26.628% |
| Monopar Therapeutics Inc. | 7.34 Million USD | 41.341% |
| Exelixis, Inc. | 2.94 Billion USD | 99.854% |
| Better Therapeutics, Inc. | 22.94 Million USD | 81.22% |
| Nurix Therapeutics, Inc. | 364.53 Million USD | 98.818% |
| Apellis Pharmaceuticals, Inc. | 788.73 Million USD | 99.454% |
| NLS Pharmaceutics AG | 1.84 Million USD | -133.322% |
| Dermata Therapeutics, Inc. | 7.97 Million USD | 45.998% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | 70.68% |
| Gritstone bio, Inc. | 177.76 Million USD | 97.576% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | 95.483% |
| TNF Pharmaceuticals, Inc. | 17.86 Million USD | 75.879% |
| Avid Bioservices, Inc. | 336.55 Million USD | 98.72% |
| Insmed Incorporated | 1.32 Billion USD | 99.676% |
| Virpax Pharmaceuticals, Inc. | 9.62 Million USD | 55.251% |
| MediWound Ltd. | 66.45 Million USD | 93.517% |
| OmniAb, Inc. | 401.98 Million USD | 98.928% |
| Alector, Inc. | 621.82 Million USD | 99.307% |
| Seres Therapeutics, Inc. | 358.6 Million USD | 98.798% |
| Checkpoint Therapeutics, Inc. | 5.37 Million USD | 19.884% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | 92.4% |
| Zai Lab Limited | 1.03 Billion USD | 99.584% |
| Revance Therapeutics, Inc. | 478.45 Million USD | 99.099% |
| Aura Biosciences, Inc. | 255.07 Million USD | 98.311% |
| Lyell Immunopharma, Inc. | 750.02 Million USD | 99.426% |
| Immunic, Inc. | 54.29 Million USD | 92.065% |
| Tarsus Pharmaceuticals, Inc. | 266.22 Million USD | 98.382% |
| Veracyte, Inc. | 1.13 Billion USD | 99.621% |
| InMed Pharmaceuticals Inc. | 11.82 Million USD | 63.557% |
| FibroGen, Inc. | 423.52 Million USD | 98.983% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -22.648% |
| Adial Pharmaceuticals, Inc. | 4.73 Million USD | 9.036% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.42 Million USD | 20.644% |
| Jazz Pharmaceuticals plc | 11.39 Billion USD | 99.962% |
| Cyclacel Pharmaceuticals, Inc. | 8.8 Million USD | 51.066% |
| Amylyx Pharmaceuticals, Inc. | 517.45 Million USD | 99.167% |
| TG Therapeutics, Inc. | 329.58 Million USD | 98.693% |
| Galecto, Inc. | 38.22 Million USD | 88.729% |
| Calithera Biosciences, Inc. | 28.67 Million USD | 84.975% |
| Fortrea Holdings Inc. | 4.35 Billion USD | 99.901% |
| KalVista Pharmaceuticals, Inc. | 235.4 Million USD | 98.17% |
| Aptevo Therapeutics Inc. | 24.84 Million USD | 82.656% |
| XBiotech Inc. | 227.24 Million USD | 98.104% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | 95.483% |
| Lyra Therapeutics, Inc. | 142.6 Million USD | 96.979% |
| Foghorn Therapeutics Inc. | 285.91 Million USD | 98.493% |
| Y-mAbs Therapeutics, Inc. | 127.86 Million USD | 96.63% |
| Theravance Biopharma, Inc. | 381.99 Million USD | 98.872% |
| Ultragenyx Pharmaceutical Inc. | 1.49 Billion USD | 99.711% |
| Metagenomi, Inc. Common Stock | 364.84 Million USD | 98.819% |
| Vaxxinity, Inc. | 44.35 Million USD | 90.286% |
| BioCryst Pharmaceuticals, Inc. | 516.96 Million USD | 99.167% |
| Gain Therapeutics, Inc. | 18.6 Million USD | 76.847% |
| Cartesian Therapeutics, Inc. | 305.05 Million USD | 98.588% |
| NexImmune, Inc. | 8.59 Million USD | 49.864% |
| Creative Medical Technology Holdings, Inc. | 10.71 Million USD | 59.79% |
| Marker Therapeutics, Inc. | 17.12 Million USD | 74.844% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 99.987% |
| Chemomab Therapeutics Ltd. | 22.15 Million USD | 80.549% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -998.395% |
| RAPT Therapeutics, Inc. | 173.32 Million USD | 97.514% |
| Ainos, Inc. | 31.84 Million USD | 86.469% |
| Pluri Inc. | 39.52 Million USD | 89.1% |
| Prothena Corporation plc | 696.38 Million USD | 99.381% |
| Adaptimmune Therapeutics plc | 282.61 Million USD | 98.475% |
| Celularity Inc. | 143.88 Million USD | 97.006% |
| Rallybio Corporation | 115.62 Million USD | 96.273% |
| Cue Biopharma, Inc. | 61.53 Million USD | 92.998% |
| MeiraGTx Holdings plc | 458.16 Million USD | 99.06% |
| Omeros Corporation | 378.26 Million USD | 98.861% |
| Humacyte, Inc. | 128.22 Million USD | 96.64% |
| Immunocore Holdings plc | 597 Million USD | 99.278% |
| Cocrystal Pharma, Inc. | 31.25 Million USD | 86.216% |
| Cidara Therapeutics, Inc. | 68.53 Million USD | 93.713% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 99.589% |
| CalciMedica, Inc. | 12.18 Million USD | 64.64% |
| Cabaletta Bio, Inc. | 253.65 Million USD | 98.301% |
| Marinus Pharmaceuticals, Inc. | 170.9 Million USD | 97.479% |
| Scholar Rock Holding Corporation | 311.03 Million USD | 98.615% |
| Sana Biotechnology, Inc. | 565.29 Million USD | 99.238% |
| Pulmatrix, Inc. | 33.95 Million USD | 87.312% |
| Elicio Therapeutics, Inc. | 27.14 Million USD | 84.128% |
| Vigil Neuroscience, Inc. | 140.85 Million USD | 96.941% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 99.669% |
| Adlai Nortye Ltd. American Depositary Shares | 130.18 Million USD | 96.69% |
| Cytokinetics, Incorporated | 824.31 Million USD | 99.477% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | 79.602% |
| Nutriband Inc. | 7.51 Million USD | 42.683% |
| Protara Therapeutics, Inc. | 78.95 Million USD | 94.543% |
| Vor Biopharma Inc. | 209.82 Million USD | 97.947% |
| Roivant Sciences Ltd. | 7.22 Billion USD | 99.94% |
| Evogene Ltd. | 51.1 Million USD | 91.568% |
| ProKidney Corp. | 420.55 Million USD | 98.975% |
| Applied Therapeutics, Inc. | 54.83 Million USD | 92.142% |
| Hoth Therapeutics, Inc. | 9.52 Million USD | 54.743% |
| BridgeBio Pharma, Inc. | 546.38 Million USD | 99.211% |
| CorMedix Inc. | 82.05 Million USD | 94.749% |
| BioLineRx Ltd. | 63.92 Million USD | 93.26% |
| Tango Therapeutics, Inc. | 402.56 Million USD | 98.93% |
| Galectin Therapeutics Inc. | 28.2 Million USD | 84.721% |
| Atai Life Sciences N.V. | 293.47 Million USD | 98.532% |
| Renovaro Biosciences Inc. | 163.12 Million USD | 97.359% |
| Aerovate Therapeutics, Inc. | 127.41 Million USD | 96.619% |
| Zentalis Pharmaceuticals, Inc. | 562.02 Million USD | 99.233% |
| Sagimet Biosciences Inc. | 96.71 Million USD | 95.545% |
| MediciNova, Inc. | 66.26 Million USD | 93.498% |
| Praxis Precision Medicines, Inc. | 87.94 Million USD | 95.101% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | 3.445% |
| GeoVax Labs, Inc. | 9.28 Million USD | 53.587% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | 99.268% |
| Biomea Fusion, Inc. | 199.92 Million USD | 97.845% |
| PTC Therapeutics, Inc. | 1.9 Billion USD | 99.774% |
| Mereo BioPharma Group plc | 66.49 Million USD | 93.521% |
| Cullinan Oncology, Inc. | 485.09 Million USD | 99.112% |
| Syndax Pharmaceuticals, Inc. | 612.88 Million USD | 99.297% |
| Absci Corporation | 234.48 Million USD | 98.162% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | 41.099% |
| 4D Molecular Therapeutics, Inc. | 339.89 Million USD | 98.732% |
| Dyne Therapeutics, Inc. | 165.08 Million USD | 97.39% |
| Kiniksa Pharmaceuticals, Ltd. | 526.32 Million USD | 99.181% |
| Ventyx Biosciences, Inc. | 277.69 Million USD | 98.448% |
| Allakos Inc. | 243.61 Million USD | 98.231% |
| Imunon, Inc. | 21.91 Million USD | 80.342% |
| Fulcrum Therapeutics, Inc. | 257.69 Million USD | 98.328% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | 99.307% |
| BioAtla, Inc. | 119.65 Million USD | 96.399% |
| NLS Pharmaceutics AG | 1.84 Million USD | -133.322% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -33.808% |
| Allogene Therapeutics, Inc. | 642.83 Million USD | 99.33% |
| Larimar Therapeutics, Inc. | 95.93 Million USD | 95.509% |
| XOMA Corporation | 234.3 Million USD | 98.161% |
| Kezar Life Sciences, Inc. | 221.23 Million USD | 98.052% |
| Cara Therapeutics, Inc. | 125.84 Million USD | 96.576% |
| aTyr Pharma, Inc. | 122.06 Million USD | 96.47% |
| Aligos Therapeutics, Inc. | 153.9 Million USD | 97.2% |
| Akero Therapeutics, Inc. | 580.27 Million USD | 99.257% |
| Viridian Therapeutics, Inc. | 490.42 Million USD | 99.121% |
| Eliem Therapeutics, Inc. | 110.46 Million USD | 96.1% |
| EyeGate Pharmaceuticals, Inc. | 15.15 Million USD | 71.574% |
| Akari Therapeutics, Plc | 4.35 Million USD | 1.065% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | 74.711% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 99.751% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -39.709% |
| UroGen Pharma Ltd. | 178.31 Million USD | 97.584% |
| Sutro Biopharma, Inc. | 470.73 Million USD | 99.085% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -675.329% |
| Orgenesis Inc. | 14.55 Million USD | 70.392% |
| Entera Bio Ltd. | 11.76 Million USD | 63.378% |
| GH Research PLC | 226.3 Million USD | 98.096% |
| Lisata Therapeutics, Inc. | 54.69 Million USD | 92.122% |
| Reneo Pharmaceuticals, Inc. | 107.43 Million USD | 95.99% |
| Xencor, Inc. | 952.69 Million USD | 99.548% |
| 60 Degrees Pharmaceuticals, Inc. | 7.78 Million USD | 44.646% |
| Replimune Group, Inc. | 487.72 Million USD | 99.117% |
| Coeptis Therapeutics Holdings, Inc. | 8.07 Million USD | 46.617% |
| Vanda Pharmaceuticals Inc. | 648.44 Million USD | 99.336% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -39.709% |
| Portage Biotech Inc. | 7.77 Million USD | 44.612% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | 3.445% |
| Olema Pharmaceuticals, Inc. | 276.94 Million USD | 98.444% |
| OncoCyte Corporation | 74.89 Million USD | 94.247% |
| Qualigen Therapeutics, Inc. | 2.03 Million USD | -111.908% |
| Processa Pharmaceuticals, Inc. | 5.78 Million USD | 25.542% |
| Purple Biotech Ltd. | 44.3 Million USD | 90.274% |
| CollPlant Biotechnologies Ltd. | 34.12 Million USD | 87.374% |
| scPharmaceuticals Inc. | 94.47 Million USD | 95.44% |
| ProMIS Neurosciences, Inc. | 18.04 Million USD | 76.123% |
| HilleVax, Inc. | 344.43 Million USD | 98.749% |
| NeuroSense Therapeutics Ltd. | 3.17 Million USD | -35.662% |
| Tharimmune, Inc. | 10.94 Million USD | 60.639% |
| Genprex, Inc. | 10.67 Million USD | 59.622% |
| Neumora Therapeutics, Inc. Common Stock | 496.19 Million USD | 99.132% |
| Atossa Therapeutics, Inc. | 96.25 Million USD | 95.524% |
| XTL Biopharmaceuticals Ltd. | 2.42 Million USD | -77.602% |
| Virios Therapeutics, Inc. | 4.16 Million USD | -3.437% |
| OKYO Pharma Limited | 1.54 Million USD | -179.551% |
| Savara Inc. | 177.56 Million USD | 97.573% |
| Curis, Inc. | 77.28 Million USD | 94.425% |
| Daré Bioscience, Inc. | 21.28 Million USD | 79.755% |
| Carmell Therapeutics Corporation | 63.94 Million USD | 93.262% |
| Titan Pharmaceuticals, Inc. | 8.08 Million USD | 46.715% |
| Achieve Life Sciences, Inc. | 19.37 Million USD | 77.757% |
| BeiGene, Ltd. | 5.8 Billion USD | 99.926% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | 64.593% |
| Revolution Medicines, Inc. Warrant | 2.08 Billion USD | 99.794% |
| Protagonist Therapeutics, Inc. | 357.95 Million USD | 98.796% |
| Erasca, Inc. | 395.29 Million USD | 98.91% |
| bluebird bio, Inc. | 619.16 Million USD | 99.304% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | 0.341% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 99.937% |
| DBV Technologies S.A. | 182.98 Million USD | 97.645% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | 0.341% |
| Moderna, Inc. | 18.42 Billion USD | 99.977% |
| Vincerx Pharma, Inc. | 18.21 Million USD | 76.348% |
| Fresh Tracks Therapeutics, Inc. | 11.58 Million USD | 62.812% |
| Molecular Templates, Inc. | 35.38 Million USD | 87.823% |
| Acrivon Therapeutics, Inc. Common Stock | 138.26 Million USD | 96.884% |
| Travere Therapeutics, Inc. | 788.91 Million USD | 99.454% |
| Monte Rosa Therapeutics, Inc. | 303.75 Million USD | 98.582% |
| Spruce Biosciences, Inc. | 103.94 Million USD | 95.855% |
| Celldex Therapeutics, Inc. | 465.62 Million USD | 99.075% |
| Cogent Biosciences, Inc. | 313.43 Million USD | 98.625% |
| MacroGenics, Inc. | 306.82 Million USD | 98.596% |
| RenovoRx, Inc. | 1.46 Million USD | -193.903% |
| Adicet Bio, Inc. | 207.29 Million USD | 97.922% |
| Prime Medicine, Inc. | 193.85 Million USD | 97.777% |
| Aditxt, Inc. | 44.57 Million USD | 90.335% |
| Adagene Inc. | 115.72 Million USD | 96.277% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | 3.268% |
| Quantum-Si incorporated | 298.25 Million USD | 98.555% |
| Maravai LifeSciences Holdings, Inc. | 1.48 Billion USD | 99.71% |
| Acurx Pharmaceuticals, Inc. | 7.7 Million USD | 44.11% |
| Voyager Therapeutics, Inc. | 351.28 Million USD | 98.773% |
| SciSparc Ltd. | 11.18 Million USD | 61.468% |
| Vericel Corporation | 353.65 Million USD | 98.782% |
| Revelation Biosciences, Inc. | 12.21 Million USD | 64.72% |
| Minerva Neurosciences, Inc. | 56.9 Million USD | 92.428% |
| Generation Bio Co. | 374.75 Million USD | 98.85% |
| Astria Therapeutics, Inc. | 254.66 Million USD | 98.308% |
| Black Diamond Therapeutics, Inc. | 158.56 Million USD | 97.283% |
| Arcutis Biotherapeutics, Inc. | 341.36 Million USD | 98.738% |
| Invivyd, Inc. | 229.18 Million USD | 98.12% |
| Relay Therapeutics, Inc. | 843.98 Million USD | 99.489% |
| Quoin Pharmaceuticals, Ltd. | 12.16 Million USD | 64.594% |
| Spero Therapeutics, Inc. | 182.39 Million USD | 97.638% |
| Artelo Biosciences, Inc. | 20.42 Million USD | 78.904% |
| 2seventy bio, Inc. | 565.42 Million USD | 99.238% |
| ADMA Biologics, Inc. | 329.18 Million USD | 98.691% |
| Clene Inc. | 52.34 Million USD | 91.768% |
| Capricor Therapeutics, Inc. | 58.73 Million USD | 92.664% |
| Boundless Bio, Inc. Common Stock | 129.89 Million USD | 96.683% |
| GeoVax Labs, Inc. | 9.28 Million USD | 53.587% |
| Recursion Pharmaceuticals, Inc. | 653.69 Million USD | 99.341% |
| Citius Pharmaceuticals, Inc. | 103.61 Million USD | 95.842% |
| Contineum Therapeutics, Inc. Class A Common Stock | 130.38 Million USD | 96.695% |
| Relmada Therapeutics, Inc. | 97.55 Million USD | 95.583% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | 93.931% |
| ALX Oncology Holdings Inc. | 242.55 Million USD | 98.224% |
| Vir Biotechnology, Inc. | 1.96 Billion USD | 99.78% |
| Evaxion Biotech A/S | 12.88 Million USD | 66.57% |
| Ocular Therapeutix, Inc. | 252.06 Million USD | 98.291% |
| Verve Therapeutics, Inc. | 752.68 Million USD | 99.428% |
| Trevena, Inc. | 40.6 Million USD | 89.389% |
| Surrozen, Inc. | 46.08 Million USD | 90.65% |
| Tyra Biosciences, Inc. | 225.85 Million USD | 98.092% |
| Cingulate Inc. | 3.49 Million USD | -23.405% |
| Galmed Pharmaceuticals Ltd. | 16.62 Million USD | 74.09% |
| Unity Biotechnology, Inc. | 65.69 Million USD | 93.441% |
| Tenax Therapeutics, Inc. | 11.68 Million USD | 63.126% |
| Terns Pharmaceuticals, Inc. | 268.51 Million USD | 98.395% |
| ACADIA Pharmaceuticals Inc. | 748.95 Million USD | 99.425% |
| Connect Biopharma Holdings Limited | 125.89 Million USD | 96.578% |
| Clearmind Medicine Inc. | 4.32 Million USD | 0.365% |
| Kronos Bio, Inc. | 213.27 Million USD | 97.98% |
| Bolt Biotherapeutics, Inc. | 159.78 Million USD | 97.303% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | 49.669% |
| Viking Therapeutics, Inc. | 368.49 Million USD | 98.831% |
| Statera Biopharma, Inc. | 21.16 Million USD | 79.647% |
| ImmunityBio, Inc. | 504.45 Million USD | 99.146% |
| Korro Bio, Inc. | 221.66 Million USD | 98.056% |
| Kineta, Inc. | 10.28 Million USD | 58.091% |
| BioVie Inc. | 25.2 Million USD | 82.908% |
| Codexis, Inc. | 136.56 Million USD | 96.845% |
| Celularity Inc. | 143.88 Million USD | 97.006% |
| Crinetics Pharmaceuticals, Inc. | 635.35 Million USD | 99.322% |
| Celcuity Inc. | 191.21 Million USD | 97.747% |
| Virax Biolabs Group Limited | 5.48 Million USD | 21.432% |
| Cibus, Inc. | 544.41 Million USD | 99.209% |
| Eledon Pharmaceuticals, Inc. | 125.89 Million USD | 96.578% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | 79.027% |
| IN8bio, Inc. | 33.7 Million USD | 87.218% |
| Kodiak Sciences Inc. | 479.37 Million USD | 99.101% |
| Annexon, Inc. | 297.67 Million USD | 98.553% |
| Adverum Biotechnologies, Inc. | 173.01 Million USD | 97.51% |
| Assembly Biosciences, Inc. | 137.46 Million USD | 96.866% |
| Avalo Therapeutics, Inc. | 20.99 Million USD | 79.476% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 99.856% |
| Eyenovia, Inc. | 28.77 Million USD | 85.029% |
| Puma Biotechnology, Inc. | 230.52 Million USD | 98.131% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | 40.357% |
| Xilio Therapeutics, Inc. | 60.92 Million USD | 92.928% |
| Arcellx, Inc. | 825.13 Million USD | 99.478% |
| Cardiff Oncology, Inc. | 81.63 Million USD | 94.722% |
| Enanta Pharmaceuticals, Inc. | 462.27 Million USD | 99.068% |
| Regulus Therapeutics Inc. | 30.75 Million USD | 85.988% |
| Moolec Science SA | 24.05 Million USD | 82.086% |
| Acumen Pharmaceuticals, Inc. | 310.12 Million USD | 98.611% |
| Geron Corporation | 394.07 Million USD | 98.907% |
| LAVA Therapeutics N.V. | 101.71 Million USD | 95.764% |
| Royalty Pharma plc | 16.38 Billion USD | 99.974% |
| Atea Pharmaceuticals, Inc. | 594.96 Million USD | 99.276% |
| Greenwich LifeSciences, Inc. | 6.99 Million USD | 38.403% |
| TFF Pharmaceuticals, Inc. | 12.02 Million USD | 64.176% |
| Mersana Therapeutics, Inc. | 226.06 Million USD | 98.094% |
| Humacyte, Inc. | 128.22 Million USD | 96.64% |
| Structure Therapeutics Inc. | 482.01 Million USD | 99.106% |
| 89bio, Inc. | 596.26 Million USD | 99.277% |
| PMV Pharmaceuticals, Inc. | 252.15 Million USD | 98.291% |
| Avenue Therapeutics, Inc. | 1.85 Million USD | -132.898% |
| Genelux Corporation | 27.89 Million USD | 84.553% |
| Trevi Therapeutics, Inc. | 89.4 Million USD | 95.181% |
| Lexicon Pharmaceuticals, Inc. | 229.42 Million USD | 98.122% |
| Notable Labs, Ltd. | 19.54 Million USD | 77.951% |
| Liquidia Corporation | 120.43 Million USD | 96.422% |
| Mustang Bio, Inc. | 17.74 Million USD | 75.715% |
| Immunovant, Inc. | 666.71 Million USD | 99.354% |
| Quantum-Si incorporated | 298.25 Million USD | 98.555% |
| Arbutus Biopharma Corporation | 144.4 Million USD | 97.016% |
| DiaMedica Therapeutics Inc. | 54.16 Million USD | 92.045% |
| Vera Therapeutics, Inc. | 175.54 Million USD | 97.546% |
| Acasti Pharma Inc. | 73.3 Million USD | 94.122% |
| MiNK Therapeutics, Inc. | 4.55 Million USD | 5.353% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | 83.503% |
| Xenon Pharmaceuticals Inc. | 964.79 Million USD | 99.553% |
| Elevai Labs, Inc. Common Stock | 5.18 Million USD | 16.981% |
| NeuroBo Pharmaceuticals, Inc. | 22.78 Million USD | 81.087% |
| Tempest Therapeutics, Inc. | 51.6 Million USD | 91.65% |
| Soleno Therapeutics, Inc. | 180.69 Million USD | 97.615% |
| PepGen Inc. | 143.05 Million USD | 96.988% |
| Moleculin Biotech, Inc. | 38.21 Million USD | 88.726% |
| United Therapeutics Corporation | 7.16 Billion USD | 99.94% |
| Nuvectis Pharma, Inc. | 19.18 Million USD | 77.542% |
| Solid Biosciences Inc. | 164.93 Million USD | 97.388% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | 26.628% |
| Immuneering Corporation | 102.58 Million USD | 95.8% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | 0.0% |
| Silo Pharma, Inc. | 7.74 Million USD | 44.377% |
| Belite Bio, Inc | 94.64 Million USD | 95.447% |
| XOMA Corporation | 234.3 Million USD | 98.161% |
| ARS Pharmaceuticals, Inc. | 233.18 Million USD | 98.152% |
| Bionomics Limited | 27.64 Million USD | 84.417% |
| Apogee Therapeutics, Inc. | 401.4 Million USD | 98.927% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | 95.988% |
| uniQure N.V. | 831.68 Million USD | 99.482% |
| Cassava Sciences, Inc. | 151.66 Million USD | 97.159% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | 3.268% |
| Poseida Therapeutics, Inc. | 273.88 Million USD | 98.427% |
| Forte Biosciences, Inc. | 38.98 Million USD | 88.947% |
| Anebulo Pharmaceuticals, Inc. | 4.07 Million USD | -5.782% |
| Enlivex Therapeutics Ltd. | 36.83 Million USD | 88.302% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | 40.357% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -22.648% |
| FibroBiologics, Inc. Common Stock | 11.82 Million USD | 63.551% |
| Altimmune, Inc. | 210.64 Million USD | 97.955% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 99.446% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | 95.988% |
| Compugen Ltd. | 121.33 Million USD | 96.449% |
| Peak Bio, Inc. | 2.59 Million USD | -65.945% |
| Zevra Therapeutics, Inc. | 172.32 Million USD | 97.5% |
| Benitec Biopharma Inc. | 52.21 Million USD | 91.748% |
| Spyre Therapeutics, Inc. | 341.85 Million USD | 98.74% |
| NKGen Biotech, Inc. Common Stock | 34.77 Million USD | 87.609% |
| Zura Bio Limited | 100.84 Million USD | 95.727% |
| PolyPid Ltd. | 15.37 Million USD | 71.971% |
| Aileron Therapeutics, Inc. | 119.28 Million USD | 96.388% |
| NKGen Biotech, Inc. Warrants | 34.77 Million USD | 87.609% |
| Instil Bio, Inc. | 325.63 Million USD | 98.677% |
| argenx SE | 4.54 Billion USD | 99.905% |
| Immunome, Inc. | 148.54 Million USD | 97.099% |
| Compass Therapeutics, Inc. | 156.87 Million USD | 97.253% |
| Verona Pharma plc | 308.12 Million USD | 98.602% |
| enGene Holdings Inc. Warrants | 86.95 Million USD | 95.045% |
| Shattuck Labs, Inc. | 159.56 Million USD | 97.3% |
| CervoMed Inc. | 9.97 Million USD | 56.795% |
| LENZ Therapeutics, Inc. | 188.45 Million USD | 97.714% |
| Plus Therapeutics, Inc. | 11.38 Million USD | 62.165% |
| Dianthus Therapeutics, Inc. | 179.4 Million USD | 97.598% |
| Moolec Science SA | 24.05 Million USD | 82.086% |
| Enveric Biosciences, Inc. | 6.11 Million USD | 29.569% |
| Inovio Pharmaceuticals, Inc. | 172.94 Million USD | 97.509% |
| AnaptysBio, Inc. | 452.38 Million USD | 99.048% |
| Design Therapeutics, Inc. | 289.64 Million USD | 98.512% |
| Leap Therapeutics, Inc. | 72.82 Million USD | 94.084% |
| NeurAxis, Inc. | 509.49 Thousand USD | -745.66% |
| Seelos Therapeutics, Inc. | 5.41 Million USD | 20.476% |
| Lumos Pharma, Inc. | 40.63 Million USD | 89.398% |
| Achilles Therapeutics plc | 161.45 Million USD | 97.331% |
| enGene Holdings Inc. Common Stock | 86.95 Million USD | 95.045% |
| 180 Life Sciences Corp. | 5.25 Million USD | 18.079% |
| Opiant Pharmaceuticals, Inc. | 70.42 Million USD | 93.882% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | 49.669% |
| Nutriband Inc. | 7.51 Million USD | 42.683% |
| ORIC Pharmaceuticals, Inc. | 254.68 Million USD | 98.308% |
| CG Oncology, Inc. Common stock | 199.3 Million USD | 97.838% |
| Fractyl Health, Inc. Common Stock | 76.21 Million USD | 94.347% |
| Rani Therapeutics Holdings, Inc. | 57.91 Million USD | 92.561% |
| MoonLake Immunotherapeutics | 526.54 Million USD | 99.182% |
| Palisade Bio, Inc. | 14.05 Million USD | 69.338% |
| Tourmaline Bio, Inc. | 210.29 Million USD | 97.951% |
| Beam Therapeutics Inc. | 1.45 Billion USD | 99.705% |
| Neurogene Inc. | 222.57 Million USD | 98.064% |
| Mirum Pharmaceuticals, Inc. | 646.62 Million USD | 99.334% |
| AEON Biopharma, Inc. | 6.84 Million USD | 37.054% |
| CARGO Therapeutics, Inc. Common Stock | 453.03 Million USD | 99.049% |
| Sesen Bio, Inc. | 189.17 Million USD | 97.722% |
| Enliven Therapeutics, Inc. | 271.86 Million USD | 98.415% |
| Kiora Pharmaceuticals, Inc. | 13.71 Million USD | 68.577% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 99.448% |
| Taysha Gene Therapies, Inc. | 266.99 Million USD | 98.386% |
| Athira Pharma, Inc. | 160.24 Million USD | 97.311% |
| Vaccinex, Inc. | 3.63 Million USD | -18.662% |
| HCW Biologics Inc. | 28.51 Million USD | 84.889% |
| XOMA Corporation | 234.3 Million USD | 98.161% |
| Nektar Therapeutics | 398.03 Million USD | 98.918% |
| Arvinas, Inc. | 1.3 Billion USD | 99.67% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | 74.711% |
| Merus N.V. | 458.49 Million USD | 99.06% |
| Omega Therapeutics, Inc. | 204.36 Million USD | 97.892% |
| Quince Therapeutics, Inc. | 180.2 Million USD | 97.609% |
| Rezolute, Inc. | 132.73 Million USD | 96.754% |
| Clene Inc. | 52.34 Million USD | 91.768% |
| Indaptus Therapeutics, Inc. | 14.92 Million USD | 71.129% |
| BeyondSpring Inc. | 24.8 Million USD | 82.632% |
| Synlogic, Inc. | 75.55 Million USD | 94.297% |
| Allarity Therapeutics, Inc. | 11.86 Million USD | 63.677% |
| Phio Pharmaceuticals Corp. | 9.36 Million USD | 53.987% |
| Peak Bio, Inc. | 2.59 Million USD | -65.945% |
| Werewolf Therapeutics, Inc. | 174.83 Million USD | 97.536% |
| Krystal Biotech, Inc. | 818.35 Million USD | 99.474% |
| Karyopharm Therapeutics Inc. | 240.43 Million USD | 98.208% |
| SpringWorks Therapeutics, Inc. | 725.78 Million USD | 99.406% |
| Lipella Pharmaceuticals Inc. | 3.57 Million USD | -20.448% |
| MannKind Corporation | 475.19 Million USD | 99.093% |
| Ikena Oncology, Inc. | 192.09 Million USD | 97.757% |
| Cyclerion Therapeutics, Inc. | 13.37 Million USD | 67.784% |
| Gyre Therapeutics, Inc. | 116.53 Million USD | 96.303% |
| Gossamer Bio, Inc. | 311.91 Million USD | 98.619% |
| CohBar, Inc. | 16.36 Million USD | 73.673% |
| Cognition Therapeutics, Inc. | 35.16 Million USD | 87.747% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | 41.099% |
| Legend Biotech Corporation | 1.84 Billion USD | 99.767% |
| Mural Oncology plc | 301.74 Million USD | 98.572% |
| Biora Therapeutics, Inc. | 31.21 Million USD | 86.197% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | 24.149% |
| Disc Medicine, Inc. | 367.99 Million USD | 98.829% |
| Champions Oncology, Inc. | 26.13 Million USD | 83.512% |
| REGENXBIO Inc. | 573.97 Million USD | 99.249% |
| Ensysce Biosciences, Inc. | 2.7 Million USD | -59.102% |
| Anavex Life Sciences Corp. | 154.38 Million USD | 97.209% |
| Cellectar Biosciences, Inc. | 12.07 Million USD | 64.32% |
| Edgewise Therapeutics, Inc. | 340.03 Million USD | 98.733% |
| Vaxart, Inc. | 91.83 Million USD | 95.308% |
| PharmaCyte Biotech, Inc. | 59.9 Million USD | 92.807% |
| Aldeyra Therapeutics, Inc. | 148.32 Million USD | 97.095% |
| Cellectis S.A. | 334.27 Million USD | 98.711% |
| Longeveron Inc. | 12.17 Million USD | 64.62% |
| Repare Therapeutics Inc. | 253.9 Million USD | 98.303% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 99.868% |
| Inozyme Pharma, Inc. | 200.84 Million USD | 97.855% |
| Revolution Medicines, Inc. | 2.08 Billion USD | 99.794% |
| Nymox Pharmaceutical Corporation | 1.62 Million USD | -165.146% |
| Third Harmonic Bio, Inc. | 277.71 Million USD | 98.449% |
| ArriVent BioPharma, Inc. Common Stock | 163.09 Million USD | 97.358% |
| AN2 Therapeutics, Inc. | 138.74 Million USD | 96.895% |
| Anixa Biosciences, Inc. | 25.52 Million USD | 83.118% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 99.981% |
| Denali Therapeutics Inc. | 1.15 Billion USD | 99.627% |
| Revelation Biosciences, Inc. | 12.21 Million USD | 64.72% |
| Veru Inc. | 50.59 Million USD | 91.484% |
| Corvus Pharmaceuticals, Inc. | 45.55 Million USD | 90.542% |
| Cingulate Inc. | 3.49 Million USD | -23.405% |
| Passage Bio, Inc. | 150.54 Million USD | 97.138% |
| Context Therapeutics Inc. | 16.06 Million USD | 73.176% |
| Exicure, Inc. | 11.58 Million USD | 62.793% |
| Day One Biopharmaceuticals, Inc. | 376.04 Million USD | 98.854% |
| Oramed Pharmaceuticals Inc. | 161.64 Million USD | 97.334% |
| Scinai Immunotherapeutics Ltd. | 17.47 Million USD | 75.34% |
| Rhythm Pharmaceuticals, Inc. | 332.74 Million USD | 98.705% |
| Nuvalent, Inc. | 732.38 Million USD | 99.412% |
| ABVC BioPharma, Inc. | 14.94 Million USD | 71.168% |
| Carisma Therapeutics, Inc. | 89.55 Million USD | 95.189% |
| Unicycive Therapeutics, Inc. | 14.19 Million USD | 69.638% |
| OmniAb, Inc. | 401.98 Million USD | 98.928% |
| Anew Medical, Inc. | 19.45 Million USD | 77.854% |
| Fennec Pharmaceuticals Inc. | 26.72 Million USD | 83.879% |
| Lipocine Inc. | 23 Million USD | 81.268% |
| Lexeo Therapeutics, Inc. Common Stock | 139.8 Million USD | 96.918% |
| Nautilus Biotechnology, Inc. | 305.56 Million USD | 98.59% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | 94.867% |
| G1 Therapeutics, Inc. | 121.54 Million USD | 96.455% |
| Bellerophon Therapeutics, Inc. | 7.93 Million USD | 45.701% |
| Sage Therapeutics, Inc. | 882.27 Million USD | 99.512% |
| Ocugen, Inc. | 64.54 Million USD | 93.325% |
| Mind Medicine (MindMed) Inc. | 124.54 Million USD | 96.54% |
| Q32 Bio Inc. | 306.11 Million USD | 98.593% |
| Brainstorm Cell Therapeutics Inc. | 4.2 Million USD | -2.391% |
| Alumis Inc. Common Stock | 89.61 Million USD | 95.192% |
| Equillium, Inc. | 50.53 Million USD | 91.473% |
| Kyverna Therapeutics, Inc. | 75.19 Million USD | 94.27% |
| Coya Therapeutics, Inc. | 41.27 Million USD | 89.561% |
| CNS Pharmaceuticals, Inc. | 1.7 Million USD | -153.321% |
| Galera Therapeutics, Inc. | 26.14 Million USD | 83.518% |
| Evelo Biosciences, Inc. | 64.44 Million USD | 93.314% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -15.602% |
| Dominari Holdings Inc. | 57.55 Million USD | 92.514% |
| Edesa Biotech, Inc. | 8.89 Million USD | 51.536% |
| vTv Therapeutics Inc. | 11.01 Million USD | 60.895% |
| Bio-Techne Corporation | 2.81 Billion USD | 99.847% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 99.54% |
| Harmony Biosciences Holdings, Inc. | 811.44 Million USD | 99.469% |
| Prelude Therapeutics Incorporated | 277.66 Million USD | 98.448% |
| Candel Therapeutics, Inc. | 41.7 Million USD | 89.668% |
| iTeos Therapeutics, Inc. | 667.58 Million USD | 99.355% |
| Nkarta, Inc. | 378.88 Million USD | 98.863% |
| BioCardia, Inc. | 2.98 Million USD | -44.246% |
| Iterum Therapeutics plc | 26.25 Million USD | 83.592% |